https://www.roche.com/media/releases/med-cor-2019-04-01
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective...
in combinationrocheipatasertibtecentriqchemotherapy
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tecentriq-atezolizumab-adjuvant-treatment-following-resection
Listen to a soundcast of the October 15, 2021 FDA approval of Tecentriq (atezolizumab) for adjuvant treatment following resection and platinum-based...
d is cfdaburstedition